Probiotic and Enzyme Supplement Classification in Thailand

Probiotic and digestive enzyme products marketed as supplements in Thailand sit under the Food Act, registered as food supplements rather than drugs, as long as the marketing stays within general health maintenance territory. The moment a brand reaches for disease-specific or clinical-grade language, that classification is at risk, and Thai FDA treats this particular boundary as one of its more actively monitored areas of supplement oversight.

How Thailand classifies probiotics and enzymes

Thai FDA classifies probiotic supplements containing live microorganisms, Lactobacillus, Bifidobacterium, Saccharomyces, and other generally recognized safe strains, and digestive enzyme supplements such as bromelain, papain, lipase, amylase, and protease from recognized food sources, as food supplements under the Notification of the Ministry of Public Health on Food Supplements. That means registration runs through the food supplement pathway with Thai FDA's Food Division, not through the drug registration system.

The classification holds as long as the product is presented for general health maintenance and stops short of disease-related claims. A probiotic marketed for "digestive support" or "gut microbiome balance" is a food supplement. The same formulation labeled as a "treatment for antibiotic-associated diarrhea" or "medical-grade probiotic for clinical use" becomes a drug requiring registration under the Drug Act B.E. 2510. Thai FDA is particularly alert to brands citing clinical study evidence, especially evidence tied to disease conditions, in probiotic marketing: the agency treats that kind of citation as an implicit therapeutic claim that shifts the product's classification from food to drug, even if the label itself never uses the word "treat."

Which probiotic strains clear registration without friction

Thai FDA accepts probiotic strains for food supplement registration on the basis of an established history of safe food use, consistent with the WHO/FAO framework for evaluating probiotic safety and efficacy. Strains from Lactobacillus acidophilus, L. rhamnosus, L. plantarum, L. reuteri, Bifidobacterium longum, B. breve, and B. bifidum are well established in Thai registration practice and typically clear without additional safety data beyond strain identification, viability specification, and standard food safety testing. These correspond to genera and species on the EFSA Qualified Presumption of Safety list, which Thai FDA references as supporting documentation. Lactococcus and Streptococcus thermophilus, along with the yeast Saccharomyces cerevisiae var. boulardii, round out the group of strains most widely accepted in Thai supplement registration.

Strains that fall outside that established group face a different path. Probiotic organisms not widely used in food, or drawn from genera outside the recognized food-grade probiotic families, including certain Bacillus strains beyond the traditional spore-forming strains already used in fermented Thai foods, engineered or modified strains, and any strain carrying a specific functional claim needing clinical substantiation, generally require novel food assessment, run under the same process as novel food ingredient review generally. Every probiotic dossier, established strain or novel one, needs strain identity documentation down to the genus, species, and strain level, including sequence-based characterization. A generic claim of "contains Lactobacillus" without strain-level identification will not clear the registration dossier, and strain designation should follow current NCBI Taxonomy nomenclature.

Enzymes: where systemic claims cross into drug territory

Digestive enzyme supplements register as food supplements when they come from recognized food sources and support general digestion. Plant-derived proteases such as bromelain from pineapple and papain from papaya, along with food-grade microbial fermentation products such as Aspergillus-derived amylases, lipases, and cellulases, are well established in Thai registration. Thai FDA's review of these dossiers focuses on confirming the source organism, the production process, the enzyme activity specification and its unit of measurement, and the dosage delivering a stated activity level, along with purity (absence of contaminants from the production organism) and activity stability across the claimed shelf life.

High-potency systemic enzyme preparations sit at the drug-food boundary in a way plant-source digestive enzymes generally do not. Serrapeptase, nattokinase, and similar enzymes marketed for cardiovascular support or systemic anti-inflammatory effects draw particular scrutiny. If these products are presented with therapeutic framing, reducing inflammation, breaking down fibrin, or otherwise implying a systemic therapeutic effect, they are likely to be classified as drugs in Thailand regardless of their food supplement status in other markets. A formulation's status abroad carries no weight here; Thai FDA makes its own determination based on the claims actually used in the Thai market.

CFU labeling: a detail that trips up more dossiers than it should

Probiotic labels in Thailand can state the genus and species of the organisms present, the CFU count per serving, and a general health support statement short of a disease claim. The CFU figure on the label has to reflect the count at the end of shelf life, at expiry, not the count at time of manufacture. That distinction matters more than it sounds: a product labeled at 10 billion CFU that hits that number fresh off the line but delivers only 1 billion CFU by expiry is mislabeled under Thai FDA's standard, full stop.

The label claim needs testing data behind it. Each batch's Certificate of Analysis has to include a CFU result supporting the label claim on a projected end-of-shelf-life basis. Many manufacturers test at manufacture and apply a survival factor to project the expiry-date count, but that survival factor itself has to be validated against stability data specific to the formulation and packaging, generated under Zone IVb storage conditions (30°C / 75% RH), the tropical storage zone Thailand falls into.

Deciding the classification before the dossier gets built

The classification question for a probiotic or enzyme product needs answering before registration work starts, not discovered midway through it. A brand that has built its identity around clinical-grade, disease-specific positioning in other markets has real decisions to make about how it presents that same product in Thailand, decisions that affect the registration pathway, the advertising strategy, and how the product can be presented on Thai e-commerce platforms. DeeMED Consulting works through this classification question with supplement brands before any dossier work begins, and reviews the CFU stability data under Zone IVb conditions specifically, since that's the technical gap we see most often in probiotic files prepared without Thailand-specific experience. Our dietary supplement registration service starts exactly here.

Multi-strain blends and combination products

Multi-strain probiotic blends, increasingly common as brands chase broader-spectrum gut health positioning, add a layer of complexity that single-strain products don't face. Each strain in the blend needs its own identity documentation at genus, species, and strain level, and the total CFU claim on the label has to be broken down accurately by strain rather than presented only as an aggregate figure, since Thai FDA's review checks that the claimed proportion of each strain is both accurate and stable through the projected shelf life. A blend where one fast-growing strain outcompetes a slower one during storage, shifting the actual strain ratio away from what's on the label by the time the product reaches expiry, is a labeling failure even if the total CFU count still holds up. Stability testing for multi-strain products therefore needs strain-specific CFU enumeration at each stability timepoint, not just a combined count, which is a more demanding and more expensive testing program than a single-strain product requires.

Combination products pairing a probiotic with a digestive enzyme, or an enzyme blend with additional botanical ingredients, are registered as a single food supplement product, but each active component still has to independently satisfy its own classification and safety requirements. A combination product does not get an easier path through registration than its most complex individual ingredient would on its own; if one enzyme in the blend sits near the drug-food boundary because of how it's positioned elsewhere in a brand's marketing, that boundary risk attaches to the entire combination product in Thailand, not just to that one ingredient in isolation. Reviewing the full ingredient list against Thai FDA's classification logic before finalizing a combination formula, rather than after, avoids having to reformulate a product that already has packaging and marketing built around it.